SCHEMBL9896202

SCHEMBL9896202

Clc1cnc(Oc2ccc3c(nnn3CC3CC3)c2Br)c(CN2CCN(c3ccccn3)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
DRD2 P14416 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NOD2 Q9HC29 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
GRM2 Q14416 3/20 0.36
ALDH1A1 P00352 2/20 0.36
PARP1 P09874 1/20 0.36
PIM1 P11309 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9896859 0.92 KDM4E (0.39) LMNAKDM4EMAPK1KMT2AGRM2
SCHEMBL9897193 0.88 PDCD1LG2 (0.38) DRD2GRM2DRD4
SCHEMBL9896706 0.88 GRM2 (0.41) GRM2
SCHEMBL9894611 0.87 GRM2 (0.42) KDM4ETDP1GRM2
SCHEMBL9896030 0.87 GRM2 (0.38) GRM2
SCHEMBL9896223 0.87 GRM2 (0.41) KDM4ETDP1GRM2
SCHEMBL9894960 0.86 GRM2 (0.35) LMNADRD2KDM4EGRM2DRD4
SCHEMBL9896827 0.86 GRM2 (0.36) DRD2RAB9AGRM2PARP1DRD4
SCHEMBL9895813 0.85 GRM2 (0.39) GRM2
SCHEMBL9896369 0.85 GRM2 (0.40) KDM4ERAB9ANPSR1GRM2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 US claimed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 US claimed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 US disclosed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 US disclosed
US-8975286-B2 Ether benzotriazole derivatives MERCK SHARP & DOHME CORP. (US) 2015-03-10 US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149677-A1 ETHER BENZOTRIAZOLE DERIVATIVES GRM2, GRIA2, GRIK2 LMNA 4659/4885DRD2 155/4885KDM4E 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.